A recent study published in JAMA Neurology identifies certain neurological hallmarks of Alzheimer’s disease in the brains of older adults with sleep apnea.
Studies of hibernating animals suggest that the molecular and synaptic integrity of neurons in the cerebral cortex that underlie self and consciousness is maintained in many cases when from the outside the brain appears dead.
A striking feature of medicine over the past few centuries has been our growing ability to bring people back from the “dead.” For most of human history, patients who were unconscious and not breathing were treated as though they had died. But the concept of resuscitation emerged as doctors grew to understand the basic function of the lungs and airways. That led to new techniques and tools capable of restoring both breathing and heartbeat — and the realization that cardiac arrest was not always a death sentence. That, in turn, gave rise to a distinction between what’s now called clinical death versus brain death.
Continue reading “‘Rebooting the brain’: Our fight to bring people back from the dead” »
Brain implants are neural implants that are used to stimulate the parts & structures of the nervous system. These implants are technical systems that communicate with the nervous system and help to enhance senses, physical movement, and memory after a stroke or other head injuries. Deep brain stimulation and spinal cord stimulation are used to treat depression, obsessive-compulsive disorder and epilepsy, among other neural disorders.
Technology has touched all aspects of our lives in this 21st century world that we live in and has, in fact, become an integral part of our lives. So much so that we start feeling incomplete as soon as we manage to get away from it.
No doubt, it has enhanced our lives in many different ways and today we can do things that we couldn’t have even imagined a few decades ago. I mean, sending a text to someone half way around the world in an instant? Almost feels like magic, doesn’t it?
This is the first reported case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy. As the number of patients with COVID-19 increases worldwide, clinicians and radiologists should be watching for this presentation among patients presenting with COVID-19 and altered mental status.
Home Radiology Recently Published PreviousNext Reviews and CommentaryFree AccessImages in Radiology COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI FeaturesNeo Poyiadji, Gassan Shahin, Daniel Noujaim, Michael Stone, Suresh Patel, Brent Griffith Neo Poyiadji, Gassan S…
Dr. Susan White and her genetics team treated two triplets from a family who had an undiagnosed neurodegenerative disorder in 2014. After one year of age, the children’s developmental skills declined. They lost visual coordination. Feeding and swallowing food became impossible. The children developed intractable seizures.
Exactly what led to their neurodegeneration was a mystery.
“As you can imagine, that was just a horrendous experience for their family and we suspected a genetic condition because of that pattern of problems occurring in both children,” White, an associate professor at Murdoch Children’s Research Institute (MCRI) and Victorian Clinical Genetics Services (VCGS), said in an interview with Being Patient.
From consciousness to cryonics, Nature’s news team answers reader questions about a remarkable piece of research.
Given the rapid development of virtual reality technology, we may very well be moving toward a time when we’re able to manage the brain’s memories.
Could we develop a similar capability? That may depend heavily upon a handful of ambitious attempts at brain-computer interfacing. But science is moving in baby steps with other tactics in both laboratory animals and humans.
Continue reading “Our brains as hard drives – could we delete, modify or add memories and skills?” »
Although innate immune cells are typically present inside tumors, they often have an inactive phenotype such that they are ineffective at killing the cancer cells or even promote tumor growth. Sarkar et al. discovered that it may be possible to reprogram these cells to a more active type using niacin (vitamin B3). The authors showed that niacin-exposed monocytes can inhibit the growth of brain tumor–initiating cells. Moreover, niacin treatment of intracranial mouse models of glioblastoma increased monocyte and macrophage infiltration into the tumors, stimulated antitumor immune responses, and extended the animals’ survival, especially when combined with the chemotherapeutic drug temozolomide.
Glioblastomas are generally incurable partly because monocytes, macrophages, and microglia in afflicted patients do not function in an antitumor capacity. Medications that reactivate these macrophages/microglia, as well as circulating monocytes that become macrophages, could thus be useful to treat glioblastoma. We have discovered that niacin (vitamin B3) is a potential stimulator of these inefficient myeloid cells. Niacin-exposed monocytes attenuated the growth of brain tumor–initiating cells (BTICs) derived from glioblastoma patients by producing anti-proliferative interferon-α14. Niacin treatment of mice bearing intracranial BTICs increased macrophage/microglia representation within the tumor, reduced tumor size, and prolonged survival. These therapeutic outcomes were negated in mice depleted of circulating monocytes or harboring interferon-α receptor–deleted BTICs. Combination treatment with temozolomide enhanced niacin-promoted survival.
The effort to create a treatment for glioblastoma has so far been unsuccessful, but a new study points to a potential step forward — the common vitamin, niacin.
As research on Alzheimer’s disease (AD) advances, a desperate need remains for an easy blood test to help diagnose the condition as early as possible. Ideally, such a test could also distinguish AD from other forms of dementia that produce similar symptoms. As published recently in Nature Medicine, an NIH-funded research team has designed a simple blood test that is on course to meet these criteria [1].
The latest work builds on a large body of work showing that one secret to predicting a person’s cognitive decline and treatment response in AD lies in a protein called tau. Using the powerful, but expensive, approach of PET scan imaging, we know that tau builds up in the brain as Alzheimer’s disease progresses. We also know that some tau spills from the brain into the bloodstream.
The trouble is that the circulating tau protein breaks down far too quickly for a blood test to offer a reliable measure of what’s happening in a person’s brain. A few years ago, researchers discovered a possible solution: test for blood levels of a slightly different and more stable version of the protein called pTau181 [2]. (The “p” in its name comes from the addition of phosphorus in a particular part of the protein’s structure.)
Continue reading “Getting Closer to a Blood Test for Alzheimer’s Disease?” »
